Implementation of evidence-based multiple focus integrated intensified TB screening to end TB (EXIT-TB) package in East Africa: a qualitative study.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
14 Mar 2023
Historique:
received: 26 12 2022
accepted: 09 02 2023
entrez: 15 3 2023
pubmed: 16 3 2023
medline: 17 3 2023
Statut: epublish

Résumé

Tuberculosis (TB) remains a major cause of morbidity and mortality, especially in sub-Saharan Africa. We qualitatively evaluated the implementation of an Evidence-Based Multiple Focus Integrated Intensified TB Screening package (EXIT-TB) in the East African region, aimed at increasing TB case detection and number of patients receiving care. We present the accounts of participants from Tanzania, Kenya, Uganda, and Ethiopia regarding the implementation of EXIT-TB, and suggestions for scaling up. A qualitative descriptive design was used to gather insights from purposefully selected healthcare workers, community health workers, and other stakeholders. A total of 27, 13, 14, and 19 in-depth interviews were conducted in Tanzania, Kenya, Uganda, and Ethiopia respectively. Data were transcribed and translated simultaneously and then thematically analysed. The EXIT-TB project was described to contribute to increased TB case detection, improved detection of Multidrug-resistant TB patients, reduced delays and waiting time for diagnosis, raised the index of TB suspicion, and improved decision-making among HCWs. The attributes of TB case detection were: (i) free X-ray screening services; (ii) integrating TB case-finding activities in other clinics such as Reproductive and Child Health clinics (RCH), and diabetic clinics; (iii), engagement of CHWs, policymakers, and ministry level program managers; (iv) enhanced community awareness and linkage of clients; (v) cooperation between HCWs and CHWs, (vi) improved screening infrastructure, (vii) the adoption of the new simplified screening criteria and (viii) training of implementers. The supply-side challenges encountered ranged from disorganized care, limited space, the COVID-19 pandemic, inadequate human resources, inadequate knowledge and expertise, stock out of supplies, delayed maintenance of equipment, to absence of X-ray and GeneXpert machines in some facilities. The demand side challenges ranged from delayed care seeking, inadequate awareness, negative beliefs, fears towards screening, to financial challenges. Suggestions for scaling up ranged from improving service delivery, access to diagnostic equipment and supplies, and infrastructure, to addressing client fears and stigma. The EXIT-TB package appears to have contributed towards increasing TB case detection and reducing delays in TB treatment in the study settings. Addressing the challenges identified is needed to maximize the impact of the EXIT-TB intervention.

Identifiants

pubmed: 36918800
doi: 10.1186/s12879-023-08069-3
pii: 10.1186/s12879-023-08069-3
pmc: PMC10013287
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

161

Subventions

Organisme : European & Developing Countries Clinical Trials Partnership 2 (EDCTP2) program supported by the European Union
ID : CSA2016S-1608

Informations de copyright

© 2023. The Author(s).

Références

Front Public Health. 2022 Feb 25;9:805726
pubmed: 35282420
Health Policy Plan. 2017 Oct 1;32(suppl_1):i6-i20
pubmed: 28981766
PLoS One. 2020 Jul 23;15(7):e0236262
pubmed: 32702073
Glob Qual Nurs Res. 2017 Nov 24;4:2333393617742282
pubmed: 29204457
BMC Health Serv Res. 2022 Jul 11;22(1):898
pubmed: 35818070
Afr Health Sci. 2010 Dec;10(4):312-9
pubmed: 21416031
BMC Public Health. 2022 Apr 5;22(1):651
pubmed: 35382794
J Clin Tuberc Other Mycobact Dis. 2021 Sep 22;25:100278
pubmed: 34622035
PLoS One. 2019 Jul 10;14(7):e0219470
pubmed: 31291352
BMC Public Health. 2015 Feb 10;15:112
pubmed: 25879547
PLOS Glob Public Health. 2022 Apr 20;2(4):e0000217
pubmed: 36962173
BMC Pediatr. 2015 Oct 01;15:142
pubmed: 26428086
Implement Sci. 2017 Mar 9;12(1):33
pubmed: 28274245
Glob Public Health. 2020 Mar;15(3):474-484
pubmed: 31516079
PLoS One. 2019 Aug 9;14(8):e0221027
pubmed: 31398220
Trop Med Int Health. 1997 Aug;2(8):715-8
pubmed: 9294539
BMC Public Health. 2020 Sep 16;20(1):1409
pubmed: 32938411
BMJ Open. 2020 Oct 1;10(10):e036625
pubmed: 33004390

Auteurs

Kahabi Isangula (K)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania. kaisa079@yahoo.com.
School of Nursing and Midwifery, Aga Khan University, Dar Es Salaam, Tanzania. kaisa079@yahoo.com.

Doreen Philbert (D)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.

Florence Ngari (F)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.

Tigest Ajeme (T)

Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.

Godfather Kimaro (G)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.

Getnet Yimer (G)

Center for Global Genomics & Health Equity, Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.

Nicholaus P Mnyambwa (NP)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.
Alliance for Africa Health and Research (A4A), Dar Es Salaam, Tanzania.

Winters Muttamba (W)

Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Division of Infection and Global Health, School of Medicine, University of St Andrews, St. Andrews, UK.

Irene Najjingo (I)

Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

Aman Wilfred (A)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.

Johnson Mshiu (J)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.

Bruce Kirenga (B)

Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

Steve Wandiga (S)

Kenya Medical Research Institute, Kisumu, Kenya.

Blandina Theophil Mmbaga (BT)

Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical University College, Moshi, Tanzania.

Francis Donard (F)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.

Douglas Okelloh (D)

Kenya Medical Research Institute, Kisumu, Kenya.

Benson Mtesha (B)

Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical University College, Moshi, Tanzania.

Hussen Mohammed (H)

College of Medicine and Health Sciences, Dire Dawa University, Dire Dawa, Ethiopia.

Hadija Semvua (H)

Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical University College, Moshi, Tanzania.

James Ngocho (J)

Kilimanjaro Clinical Research Institute and Kilimanjaro Christian Medical University College, Moshi, Tanzania.

Sayoki Mfinanga (S)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.

Esther Ngadaya (E)

Muhimbili Centre, National Institute for Medical Research, Dar Es Salaam, Tanzania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH